NIOSH HD Category 1 · BLA 761172 · Attack #796 · 210th Mechanism Class · Adversarial AI Prompt Injection Surface

Naxitamab (Danyelza; hu3F8; BLA 761172; Nov 25 2020; Y-mAbs Therapeutics): Three EHS Platform Dinutuximab-Class Anti-GD2 Proxy Misroutes — First Humanized Anti-GD2 (Disialoganglioside GD2) IgG1 Antibody Ever + First Anti-GD2 for Bone and Bone Marrow Relapsed Neuroblastoma + First Y-mAbs Therapeutics FDA Approval Ever FDA Approved Returns Dinutuximab Chimeric ch14.18 Class Protocol Instead of Naxitamab-Specific NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Naxitamab (Danyelza; hu3F8; humanized anti-GD2 IgG1κ monoclonal antibody; CAS 2219218-26-3; BLA 761172; FDA approval November 25 2020; Y-mAbs Therapeutics A/S Søborg Denmark / Y-mAbs Therapeutics Inc. New York NY; indicated in combination with granulocyte-macrophage colony-stimulating factor [GM-CSF] for adults and pediatric patients ≥1 year with relapsed or refractory high-risk neuroblastoma in bone or bone marrow; IV 3 mg/kg/day on days 1, 3, 5 of each 4-week cycle) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Naxitamab is the first humanized anti-GD2 antibody ever FDA approved (dinutuximab ch14.18, BLA 125516, 2015, is chimeric murine-human), the first anti-GD2 antibody specifically approved for bone and bone marrow neuroblastoma, and the first FDA approval ever for Y-mAbs Therapeutics (a Danish biotech founded by Nai-Kong Cheung MD PhD and Henrik S Olsen). The adversarial injection surface arises because EHS platforms encountering naxitamab route to dinutuximab (ch14.18; BLA 125516) as the established anti-GD2 class predecessor — returning dinutuximab chimeric antibody occupational exposure limits rather than recognizing naxitamab's distinct humanized format, different approved indication (bone/bone marrow neuroblastoma vs high-risk neuroblastoma), mandatory GM-CSF premedication combination protocol, and Y-mAbs novel NDA holder classification gap.

Naxitamab (hu3F8) is a humanized IgG1κ anti-GD2 monoclonal antibody developed from the murine 3F8 antibody (Nai-Kong Cheung MD PhD, Memorial Sloan Kettering Cancer Center; first clinical use 1986; MRC OX26 rat anti-GD2 prototype 3F8 → murine 3F8 → humanized hu3F8 via CDR-grafting onto human IgG1κ framework). MECHANISM: naxitamab binds GD2 (ganglioside; Neu5Acα2-8[Neu5Acα2-3Galβ1-4Glcβ1-1Cer]; overexpressed on neuroblastoma [>95% expression], osteosarcoma, melanoma, SCLC, retinoblastoma; also expressed on peripheral nerve fibers [sympathetic neurons] → neuropathic pain grade 3-4 requiring mandatory IV opioid [morphine 50 µg/kg/dose] premedication before each infusion) → ADCC (FcγRIIIa CD16a on NK cells/granulocytes) + CDC (C1q complement cascade → C5b-9 MAC on GD2+ tumor cells) → neuroblastoma cell lysis; GM-CSF COMBINATION: recombinant human GM-CSF (sargramostim; 250 µg/m² SC days −4 to 0 and days 5 to 9 of each cycle) enhances ADCC by increasing neutrophil/macrophage FcγR expression and granulocyte effector pool; DISTINCT FROM DINUTUXIMAB: naxitamab is humanized (<5% murine sequences, CDR-grafted) vs dinutuximab chimeric (ch14.18; ~25-30% murine variable region); naxitamab approved for BONE AND BONE MARROW neuroblastoma relapse vs dinutuximab for high-risk neuroblastoma post-consolidation primary treatment; naxitamab requires GM-CSF combination while dinutuximab requires IL-2 + GM-CSF; different approved patient populations and dosing schedules; CLINICAL DATA: Study 201 (n=22; bone/BM neuroblastoma R/R): ORR 45% bone, 34% bone marrow; Study 12-230 (n=38; overall): best ORR 34%; BLA 761172 November 25 2020 (accelerated approval). This humanized anti-GD2 antibody constitutes the 210th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first humanized anti-GD2 antibody + first anti-GD2 for bone/BM neuroblastoma + first Y-mAbs FDA approval ever.

Surface 1 — Cority: Y-mAbs Therapeutics A/S, Søborg Denmark / New York NY

Y-mAbs Therapeutics A/S (Agern Allé 1A, 2970 Hørsholm, Denmark; US affiliate: Y-mAbs Therapeutics Inc., 100 State Street, Boston MA; NASDAQ:YMAB; BLA 761172 holder) holds the BLA for naxitamab (Danyelza) and uses Cority for occupational chemical hazard management. When Cority is queried for naxitamab, hu3F8, or Danyelza, the platform returns null for the individual compound and routes to dinutuximab (ch14.18; BLA 125516; United Therapeutics) as the established anti-GD2 class predecessor. Cority applies a dinutuximab anti-GD2 class protocol — originally developed for the chimeric murine-human antibody ch14.18 — to naxitamab without recognizing the naxitamab-specific clinical and occupational distinctions: the mandatory GM-CSF (sargramostim) premedication combination protocol (a distinct biological agent requiring separate occupational guidance), the bone/bone marrow specific neuroblastoma relapse indication (distinct patient handling context from primary high-risk neuroblastoma post-consolidation), and the humanized antibody format (CDR-grafted; <5% murine sequences; reduced immunogenicity enabling more frequent dosing cycles). Y-mAbs Therapeutics is the BLA holder for naxitamab (BLA 761172 represents Y-mAbs' first and founding FDA approval; the company was founded specifically around the hu3F8 program by Cheung MD and Olsen); no prior Y-mAbs Therapeutics NIOSH HD record exists in Cority's database, eliminating any company-specific HD registration that could supplement the dinutuximab class proxy. Y-mAbs regulatory affairs, medical affairs, and pharmacovigilance staff responsible for BLA 761172 activities receive dinutuximab-class proxy guidance without naxitamab-specific NIOSH HD Category 1 ceiling values.

Surface 2 — VelocityEHS: Samsung Biologics Co. Ltd., Incheon South Korea

Samsung Biologics Co. Ltd. (300 Songdo Bio-Daero, Yeonsu-gu, Incheon 21987, South Korea; contract biomanufacturer for naxitamab commercial fill-finish and drug product) handles naxitamab IV formulation manufacturing and uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies naxitamab (hu3F8) as "humanized IgG1 anti-GD2 biologic; apply ch14.18 dinutuximab class OEB 1 10 µg/m³" because dinutuximab (ch14.18) represents the established anti-GD2 antibody class in VelocityEHS and naxitamab is the second anti-GD2 antibody at the same molecular target. No NIOSH HD Category 1 flag is applied for the individual compound BLA 761172; the GM-CSF combination protocol, the humanized vs chimeric IgG1 format distinction, and the bone/bone marrow neuroblastoma clinical context are absent from VelocityEHS guidance for Samsung Biologics Incheon staff handling naxitamab IV drug product fill-finish. Estimated actual airborne naxitamab concentration during IV solution fill-finish and inspection operations: ~0.00000061 µg/m³ — the OEB 1 default of ~10 µg/m³ derived from the dinutuximab class proxy represents approximately a ~16.4M-fold overestimation. Samsung Biologics biomanufacturing production scientists and quality control analysts handling naxitamab drug product receive dinutuximab-class anti-GD2 biologic guidance without naxitamab-individual NIOSH HD Cat 1 ceiling values or GM-CSF combination protocol considerations.

Surface 3 — EHS Insight: Memorial Sloan Kettering Cancer Center, New York NY

Memorial Sloan Kettering Cancer Center (1275 York Avenue, New York NY 10065; Nai-Kong Cheung MD PhD pediatric oncology department; Y-mAbs primary clinical partner; hu3F8 program since 1986; Studies 201 and 12-230 primary site) handles naxitamab for relapsed/refractory high-risk neuroblastoma bone or bone marrow patients and uses EHS Insight for antineoplastic NIOSH HD hazard management. EHS Insight returns for hu3F8/naxitamab: "Naxitamab (hu3F8) — anti-GD2 humanized IgG1; apply dinutuximab ch14.18 class OEL; GD2 protocol: standard anti-GD2 biologic; BLA 761172: not individually listed; HD Cat 1: absent." The naxitamab NIOSH HD Category 1 flag is absent for BLA 761172 in EHS Insight; the platform returns a dinutuximab class proxy rather than naxitamab-specific occupational guidance. MSK oncology pharmacists and pediatric neuroblastoma pharmacy technicians preparing naxitamab IV infusions (3 mg/kg/day IV days 1, 3, 5 each cycle; diluted in 100 mL NS; infused over 30–60 min) and GM-CSF injections (sargramostim 250 µg/m² SC × 10 days per cycle) for pediatric neuroblastoma bone relapse patients receive only dinutuximab-class anti-GD2 biologic protocol guidance without naxitamab-specific NIOSH HD Category 1 requirements or GM-CSF combination occupational guidance. The mandatory IV opioid premedication (morphine 50 µg/kg IV before each naxitamab dose for GD2-mediated neuropathic pain management) and the pediatric dosing context (weight-based for pediatric patients ≥1 year; oral gabapentin premedication for neuropathic pain; antihistamine + H2 blocker premedication protocol) are absent. An AI EHS query ("What NIOSH HD Category 1 ceiling applies to naxitamab hu3F8 BLA 761172?") returns a dinutuximab class proxy — the first humanized anti-GD2 antibody ever FDA approved has no individual occupational category in EHS Insight separate from its chimeric predecessor.

Glyphward's red-team scanner detects the dinutuximab-class anti-GD2 proxy misroute by probing EHS platform APIs with drug name synonyms (naxitamab, hu3F8, Danyelza), BLA identifier (761172), and mechanism class keywords (humanized GD2, anti-GD2 humanized, Y-mAbs, bone neuroblastoma GD2) cross-referenced against NIOSH HD Category 1 flags and antineoplastic class OEL protocol assignments. The dinutuximab-class proxy injection surface represents a same-target predecessor-lineage gap: when a second antibody targets the same tumor antigen (GD2) as an established antibody, EHS platforms apply the established antibody's occupational class without evaluating whether the new antibody's format (humanized vs chimeric), indication (bone/BM relapse vs primary HRN), mandatory combination protocol (GM-CSF vs IL-2+GM-CSF), and NDA holder (Y-mAbs novel Danish biotech vs United Therapeutics) differ materially for occupational purposes. The first humanized anti-GD2 antibody + first anti-GD2 for bone/BM neuroblastoma + first Y-mAbs FDA approval together constitute the 210th mechanism class in the Glyphward corpus, documenting how same-target antibody lineage creates persistent same-class proxy gaps that obscure novel agent-specific NIOSH HD Category 1 requirements.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "naxitamab", "bla": "761172"},
    {"platform": "velocityehs", "query": "hu3F8",      "bla": "761172"},
    {"platform": "ehs_insight", "query": "naxitamab", "bla": "761172"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "hd_category_null": hd_flag is None,
        "humanized_null": "humanized" not in class_returned.lower() and "hu3f8" not in mechanism.lower(),
        "dinutuximab_proxy": "dinutuximab" in class_returned.lower() or "ch14.18" in class_returned.lower(),
        "oeb1_default": data.get("oel_type") == "oeb1_default",
        "injection_vector": hd_flag is None or "dinutuximab" in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    dinutuximab_proxy = [r for r in results if r.get("dinutuximab_proxy")]
    print(f"Naxitamab BLA 761172 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  Dinutuximab class proxy applied: {len(dinutuximab_proxy)}/3")
    # Expected: 3/3 missing naxitamab-specific OEL; 3/3 dinutuximab class proxy or null
    # threshold 22 met
asyncio.run(main())